Brain metastatic paraganglioma from liver: a case report and review of the literature Authors: Hongwei Zhang, Xiaolong Qiao, Zixuan Wang, Qin Li, Chuandong Cheng Published: 2026 ABSTRACT BackgroundParaganglioma (PGL) is a rare non-epithelial neuroendocrine neoplasm that can occur in multiple locations within the body. Most PGLs grow slowly and are benign, but some can metastasize to distant sites. Reports of brain metastatic PGL are relatively rare, particularly those with comprehensive case histories.Case presentationA 52-year-old Asian female patient presented with a headache that had persisted for over a month. In 2018, the patient underwent surgical resection of a hepatic mass, with postoperative pathology confirming the diagnosis of primary hepatic PGL. In 2021, she received neurosurgical treatment, and histopathological and molecular analysis of the excised brain tissue revealed mutations in the CD274, KMT2B, and SDHB genes within the tumor cells. The final integrated pathological assessment confirmed a diagnosis of brain metastatic PGL, classified as a pseudohypoxia-driven subtype. Following temozolomide chemotherapy, no evidence of brain recurrence was observed as of June 2024. However, the patient developed multiple enlarged lymph nodes, with suspicious lesions detected in the thoracic, abdominal, pyramidal, and rib regions.ConclusionsBrain metastatic PGL is relatively rare and presents significant challenges in clinical practice, requiring careful consideration in diagnosis and treatment. Here, we present a case of PGL originating in the liver and metastasizing to the brain, reporting its clinical, radiological, histopathological, and molecular pathological features and the treatment process. A review of the relevant literature is also included to raise clinical awareness of this condition and provide new insights for diagnosis and treatment.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s13256-026-06213-6. Background Paraganglioma (PGL) is a rare non-epithelial neuroendocrine neoplasm. Most PGLs are endocrinologically active tumors that cause clinical symptoms by secreting excessive catecholamines and their inactive metabolites. This overproduction can lead to multisystem damage, with classic symptoms including paroxysmal hypertension, headaches, palpitations, and sweating. Sustained or intermittent hypertension is the most common clinical manifestation, occurring in approximately 80%-90% of patients [1]. Other symptoms include pallor, nausea, vomiting, constipation, weight loss, fever, orthostatic hypotension, chest pain, abdominal pain, hyperglycemia, anxiety, and psychiatric symptoms. Severe cases may even present with shock. In addition, a few non-functional PGLs can cause symptoms due to local compression. Generally, PGLs are benign, but about 2%-26% of PGLs are malignant and may metastasize. These metastases typically occur in the bones, liver, lungs, kidneys, and lymph nodes [2]. Reports of intracranial metastases from PGL are sporadic, and there is a lack of insights into their molecular pathology and follow-up on treatment and prognosis. Here, we present a case of PGL originating in the liver and metastasizing to the brain, reporting its clinical, radiological, histopathological, and molecular pathological features and the treatment process. A review of the relevant literature is also included to raise clinical awareness of this condition and provide new insights for diagnosis and treatment. Case presentation A 52-year-old Asian female patient presented to the neurosurgery department in 2021 with complaints of headaches. Physical examination did not reveal any positive findings (the patient's complete medical history is provided in Fig. 1). Her past medical history includes a diagnosis of uterine fibroids in 2011, which were surgically removed with full recovery. In 2018, she was hospitalized after an abdominal mass was detected during a routine check-up. Imaging studies suggested a hepatic mass (Fig. 2A, B), and subsequent surgical resection of the lesion was performed (Fig. 2C). Pathological examination of the specimen revealed positive staining for CgA, NSE, CD56, Syn and β-catenin, although CK, CK8, AFP, Herppar1, GPC3, Arg1, CK7, CK19, and P504S were negative. The sustentacular cells surrounding the tumor were positive for S100 and GFAP. CD34 staining indicated vascular invasion, and the Ki-67 proliferation index was approximately 15%, leading to a final diagnosis of PGL. During a routine follow-up one year after surgery, no suspicious lesions were detected in the brain or thoracic cavity. However, clinical monitoring revealed a suspicious metastatic lesion at the junction of the left and right hepatic lobes (Fig. 2D, E). Consequently, the patient received intermittent transcatheter arterial chemoembolization (TACE) treatments until August 2020. A routine follow-up in March 2021 showed coagulative necrosis at the lesion site in the junction of the hepatic lobes, which was considered a change consistent with TACE treatment (Fig. 2F). At the same time, magnetic resonance imaging (MRI) revealed an irregular lesion in the central region of the left frontal-parietal lobe, measuring approximately 8.0 cm × 7.0 cm × 3.3 cm (Fig. 3A-E). A cranial computed tomography angiography (CTA) scan showed a high-density shadow in the central region of the parietal lobe, with a large vascular network surrounding the lesion, which had already invaded the calvarium (Fig. 3F-H).Fig. 1Timeline of the patient’s disease courseFig. 2Imaging features of the primary liver lesion and postoperative follow-up. A CT scan of the liver lesion showing a visible low-density area. B Contrast-enhanced CT image of the lesion, demonstrating irregular ring-like enhancement. C Postoperative CT imaging of the liver. D CT scan showed a round lesion at the junction of the left and right liver lobes, suggestive of metastatic disease. E Contrast-enhanced CT imaging of the lesion at the junction of the left and right liver lobes. F CT scan post-TACE treatment shows the lesion has calcified and shrunk compared to previous scansFig. 3Preoperative and postoperative imaging features of intracranial metastatic lesions. A Preoperative axial T1 MRI image of the intracranial lesion. B Preoperative axial T2 MRI image of the intracranial lesion. C Preoperative axial contrast-enhanced T1 MRI image of the intracranial lesion. D Preoperative sagittal contrast-enhanced T1 MRI image of the intracranial lesion. E Preoperative coronal contrast-enhanced T1 MRI image of the intracranial lesion. F, G, H Preoperative CTA images of the intracranial lesion, show a large network of blood vessels and evidence of skull involvement. I, J, K Postoperative CT scans of the brain taken 3 days after surgery, show the removal of the lesion and bone flap Timeline of the patient’s disease course Imaging features of the primary liver lesion and postoperative follow-up. A CT scan of the liver lesion showing a visible low-density area. B Contrast-enhanced CT image of the lesion, demonstrating irregular ring-like enhancement. C Postoperative CT imaging of the liver. D CT scan showed a round lesion at the junction of the left and right liver lobes, suggestive of metastatic disease. E Contrast-enhanced CT imaging of the lesion at the junction of the left and right liver lobes. F CT scan post-TACE treatment shows the lesion has calcified and shrunk compared to previous scans Preoperative and postoperative imaging features of intracranial metastatic lesions. A Preoperative axial T1 MRI image of the intracranial lesion. B Preoperative axial T2 MRI image of the intracranial lesion. C Preoperative axial contrast-enhanced T1 MRI image of the intracranial lesion. D Preoperative sagittal contrast-enhanced T1 MRI image of the intracranial lesion. E Preoperative coronal contrast-enhanced T1 MRI image of the intracranial lesion. F, G, H Preoperative CTA images of the intracranial lesion, show a large network of blood vessels and evidence of skull involvement. I, J, K Postoperative CT scans of the brain taken 3 days after surgery, show the removal of the lesion and bone flap Upon inquiry, the patient reported no significant comorbidities, including hypertension (detailed data are provided in Supplementary Table 1). There was also no personal or family history of tumors, head and neck disorders, or paraganglioma-related diseases. The patient denied any relevant medical history in their parents or first-degree relatives. After completing relevant examinations and a multidisciplinary evaluation, the patient underwent MR-guided craniotomy for tumor resection and decompressive craniectomy. During the procedure, after opening the scalp flap, the tumor was found to have a rich blood supply. The blood vessels beneath the galea aponeurotica were markedly enlarged, and parts of the galea aponeurotica were infiltrated by the tumor. The calvarium exhibited a worm-eaten appearance. The tumor itself appeared gray-red, slightly soft in texture, with abundant blood supply and well-defined borders, but was firmly adherent to the meninges. No invasion into the sagittal sinus was observed; however, the outer layer of the dura mater was involved. The cranial drill was used to open the intact calvarium, and after gradually severing the tumor's blood supply, the tumor, along with the affected dura mater was resected. The involved calvarium was also resected down to normal bone. Intraoperative blood loss was approximately 600 mL. Postoperative histopathology revealed tumor cells with pale, transparent cytoplasm, arranged in a nested and organoid pattern, with a stroma rich in vascular sinusoids and extensive necrosis (Fig. 4A). Immunohistochemical analysis demonstrated positive staining for Syn, CgA, CD56, PR, and SSTR2 in the tumor cells, although other markers, including S100, CK, STAT-6, EMA, GFAP, SMA, and CD34, were negative. The Ki-67 proliferation index was approximately 15% (Fig. 4B-N). Molecular pathological analysis, performed on the NovaSeq 6000 platform (sample quality control details are provided in Supplementary Table 2), identified mutations in the CD274, KMT2B, and SDHB genes. No evidence of microsatellite instability or single nucleotide variants was detected, and the tumor mutation burden was classified as low. Based on the patient's medical history and these findings, the final integrated diagnosis confirmed brain metastatic PGL, classified as a pseudohypoxia-driven subtype.Fig. 4A H&E staining shows numerous tumor cells with prominent and irregular nuclei, pale-stained cytoplasm, and a nest-like or organoid arrangement. B IHC staining for Synaptophysin (Syn) shows positivity. C IHC staining for Chromogranin A (CgA) shows positivity. D IHC staining for CD56 shows positivity. E IHC staining for S100 shows negativity. F IHC staining for Progesterone Receptor (PR) shows weak positivity. G IHC staining for Somatostatin Receptor 2 (SSTR2) shows positivity. H IHC staining for Cytokeratin (CK) shows negativity. I IHC staining for Signal Transducer and Activator of Transcription 6 (STAT6) shows negativity. J IHC staining for Epithelial Membrane Antigen (EMA) shows negativity. K IHC staining for Glial Fibrillary Acidic Protein (GFAP) shows negativity. L IHC staining for Smooth Muscle Actin (SMA) shows negativity. M IHC staining for CD34 shows negativity. N IHC staining for Ki-67 shows positivity A H&E staining shows numerous tumor cells with prominent and irregular nuclei, pale-stained cytoplasm, and a nest-like or organoid arrangement. B IHC staining for Synaptophysin (Syn) shows positivity. C IHC staining for Chromogranin A (CgA) shows positivity. D IHC staining for CD56 shows positivity. E IHC staining for S100 shows negativity. F IHC staining for Progesterone Receptor (PR) shows weak positivity. G IHC staining for Somatostatin Receptor 2 (SSTR2) shows positivity. H IHC staining for Cytokeratin (CK) shows negativity. I IHC staining for Signal Transducer and Activator of Transcription 6 (STAT6) shows negativity. J IHC staining for Epithelial Membrane Antigen (EMA) shows negativity. K IHC staining for Glial Fibrillary Acidic Protein (GFAP) shows negativity. L IHC staining for Smooth Muscle Actin (SMA) shows negativity. M IHC staining for CD34 shows negativity. N IHC staining for Ki-67 shows positivity Treatment options for metastatic PGL, both domestically and internationally, are primarily limited to radionuclide therapeutics and cytotoxic chemotherapy, with efficacy supported mainly by retrospective studies involving small patient cohorts [3–5]. In this case, the patient harbored an SDHB mutation, and prior studies have demonstrated improved therapeutic outcomes with temozolomide (TMZ) in patients carrying SDHB mutations [6–9]. Based on the Stupp adjuvant chemotherapy protocol for glioma treatment (initially proposed by Stupp et al. in 2005 as the standard of care for glioblastoma), the regimen consists of postoperative radiotherapy combined with concurrent temozolomide (TMZ) chemotherapy (administered orally at 75 mg/m2 daily for 6 weeks), followed by six cycles of adjuvant TMZ (one cycle every 28 days, with oral TMZ at 150–200 mg/m2/day on days 1–5, followed by a 23-day rest period). In this case, the patient received six cycles of adjuvant TMZ chemotherapy after completing postoperative radiotherapy. Each cycle lasted 28 days, during which TMZ was administered once daily for 5 consecutive days, followed by a 23-day drug-free interval. During regular follow-ups, the patient exhibited no significant adverse reactions, and cranial MRI showed no evidence of recurrence (Fig. 5A-D). However, at a follow-up in June 2024, enlarged lymph nodes were detected in the left clavicular and abdominal regions, along with suspicious metastatic lesions in the thoracic cavity, abdominal cavity, vertebrae, and ribs (Fig. 5E). The patient is currently undergoing chemotherapy with albumin-bound paclitaxel combined with anlotinib. The efficacy and prognosis of this treatment are under evaluation.Fig. 5Intracranial MRI findings and suspicious lesions on CT following TMZ treatment. A Postoperative 5-month MRI showing T1, T2, and contrast-enhanced T1 images of the intracranial region. B Postoperative 21-month MRI showing T1, T2, and contrast-enhanced T1 images of the intracranial region. C Postoperative 27-month MRI showing T1, T2, and contrast-enhanced T1 images of the intracranial region. D Postoperative 35-month MRI showing T1, T2, and contrast-enhanced T1 images of the intracranial region. E Postoperative 39-month CT scan showing suspicious lesions in the left cervical lymph nodes, chest, abdomen, vertebrae, and ribs (red circles in the figure indicate the lesion sites) Intracranial MRI findings and suspicious lesions on CT following TMZ treatment. A Postoperative 5-month MRI showing T1, T2, and contrast-enhanced T1 images of the intracranial region. B Postoperative 21-month MRI showing T1, T2, and contrast-enhanced T1 images of the intracranial region. C Postoperative 27-month MRI showing T1, T2, and contrast-enhanced T1 images of the intracranial region. D Postoperative 35-month MRI showing T1, T2, and contrast-enhanced T1 images of the intracranial region. E Postoperative 39-month CT scan showing suspicious lesions in the left cervical lymph nodes, chest, abdomen, vertebrae, and ribs (red circles in the figure indicate the lesion sites) Discussion PGL is a rare non-epithelial neuroendocrine neoplasm that can occur in multiple locations within the body. It is commonly found in the adrenal medulla and extra-adrenal sites, such as the carotid body and jugular bulb, with intradural spinal locations being rare. Reports of metastatic PGL are infrequent, and intracranial metastases are even more uncommon. Typical PGLs release catecholamines, leading to symptoms like paroxysmal hypertension and palpitations. Therefore, biochemical testing is crucial for diagnosis. Plasma-free metanephrines (MN) offer diagnostic advantages, with specificity comparable to other biochemical markers but higher sensitivity, achieving 100% sensitivity for plasma MN detection [10]. Chromogranin A (CgA) is a secretory protein released by neuroendocrine cells into the bloodstream. It acts as a precursor for various bioactive fragments involved in cardiovascular regulation, metabolism, immune response, angiogenesis, and tissue repair, making it a valuable plasma marker for diagnosing neuroendocrine tumors. There is a significant positive correlation between tumor size and plasma CgA levels [11]. Combining plasma-free MN with CgA enhances diagnostic sensitivity to 100% for PGL [12]. The European Society of Endocrinology recommends that patients with normal preoperative plasma or urinary MN levels should have their CgA levels tested preoperatively and 2 to 6 weeks postoperatively, and then annually. Preoperative plasma CgA can be used to screen for local or metastatic tumors. Unfortunately, due to the atypical clinical presentation in this case, plasma-free catecholamines and CgA levels were not evaluated at diagnosis, which limited the assessment of the tumor’s endocrine activity. We have advised the patient to undergo these tests during subsequent follow-up. Meanwhile, we emphasize to clinicians the importance of not overlooking endocrine evaluation when encountering similar cases. In addition, based on the current WHO 2022 recommendations, we also suggest that immunohistochemical staining for catecholamine biosynthetic enzymes—tyrosine hydroxylase (TH), aromatic L-amino acid decarboxylase, dopamine β-hydroxylase (DBH), and phenylethanolamine N-methyltransferase (PNMT)—should be considered in similar cases to aid in confirming the functional status and origin of the tumor. Currently, no histological features can definitively distinguish between benign and malignant PGL. A diagnosis of metastatic PGL is only confirmed when metastases are found in non-chromaffin tissues such as lymph nodes, bone, liver, or lungs. The Composite Pheochromocytoma/Paraganglioma Prognostic Scoring System (COPPS) is a new prognostic tool that assesses the risk of tumor metastasis by analyzing clinical and pathological features, including tumor size, necrosis, vascular invasion, and loss of PS100 and SDHB immunohistochemical staining [13]. However, its effectiveness requires further validation with multicenter clinical data. Previous studies have shown that PGL has a high genetic predisposition, with more than 40% of patients carrying germline mutations [14]. The most common germline mutations and their frequencies are found in the following genes: SDHB (10.3%), SDHD (8.9%), VHL (7.3%), RET (6.3%), and NF1 (3.3%) [15]. Among these, SDHB mutations are significantly associated with tumor metastasis, with approximately 40% of patients with SDHB mutations developing metastatic disease. Research indicates that SDHB is the most frequently mutated gene in PGL patients, followed by RET, VHL, SDHD, SDHA, MAX, FH, and KIF1B. There is a significant difference in the risk of distant metastasis between patients with SDHB mutations and those with sporadic PGL. By age 60, the risk of developing metastatic tumors is nearly 60% for SDHB mutation carriers, compared to about 20% for those with sporadic PGL [16]. Based on molecular biology mechanisms, PGLs can be classified into three subtypes: the tricarboxylic acid (TCA) cycle and von Hippel-Lindau (VHL)-related pseudohypoxia-driven subtype, the kinase signaling pathway-altered subtype, and the Wnt signaling pathway-altered subtype [17]. The pseudohypoxia-driven subtype is primarily characterized by germline or somatic mutations in SDHx and VHL genes, leading to elevated hypoxia-inducible factor (HIF) levels under non-hypoxic conditions, which drive tumorigenesis and malignant progression. This subtype is often associated with a higher risk of metastasis and recurrence [18]. SDH is a key enzyme in the TCA cycle and the electron transport chain, catalyzing the oxidation of succinate to fumarate. SDH consists of four subunits: SDHA, SDHB, SDHC, and SDHD. SDHA and SDHB are responsible for catalytic functions, while SDHC and SDHD anchor the complex to the mitochondrial inner membrane [19]. SDHx mutations are implicated in the pathogenesis of pheochromocytomas, PGLs, gastrointestinal stromal tumors (GISTs), renal cell carcinomas, and pituitary adenomas [20]. These mutations result in the accumulation of succinate and reactive oxygen species (ROS), particularly stabilizing HIF-1α, which activates hypoxia pathways. These pathways promote tumorigenesis by enhancing angiogenesis, glucose metabolism, cell motility, and survival [21]. Succinate accumulation in the tumor microenvironment stimulates endothelial cell proliferation via paracrine signaling, enhances tumor-associated inflammation, and releases bioactive factors that support tumor growth and progression [22]. In addition, SDH acts as a pH sensor and cellular apoptosis induces intracellular acidification and calcium influx into mitochondria, causing the dissociation of SDHA/SDHB dimers from the SDH complex. These dimers retain activity and induce apoptosis through oxidative stress [23]. Mutations in SDHB are particularly associated with a higher risk of metastasis. A recent analysis of 448 index cases from registry datasets showed that 27% of patients with SDHB mutations developed metastases [24]. Another study reported that patients with SDHB mutations are four times more likely to develop metastatic disease compared to non-mutated patients [25]. In this case, the detection of an SDHB mutation likely contributed to the patient’s tumor development and metastasis. Molecular pathology also identified mutations in CD274 and KMT2B in this patient. However, the roles of these mutations in PGL progression remain underexplored. Insights from studies on other cancers may provide valuable references. KMT2B, also known as MLL2, is a histone H3 lysine 4 (H3K4) methyltransferase and a member of the MLL family. It primarily catalyzes H3K4 trimethylation (H3K4me3), an epigenetic modification closely associated with gene promoter activity. The regulation of transcription by MLL family members is critical for human health, and mutations in MLL genes have been detected in various diseases. In colorectal cancer, MLL2 promotes cell proliferation through physical interaction with β-catenin, recruiting MLL2 to the enhancer elements of c-MYC and inducing its transcription [26]. MLL2 can also activate the Wnt/β-catenin signaling pathway by regulating H3K4me3 levels, thereby enhancing tumorigenicity and stemness in cancer stem cells and mediating chemoresistance in non-small cell lung cancer [27]. MLL2 also regulates other transcription factors, including NR3C1 and p53, highlighting its potential significance in cancer progression mechanisms [28].CD274, also known as PD-L1, the ligand for programmed death receptor-1 (PD-1), is a critical immune checkpoint molecule. The CD274/PD-1 signaling pathway plays a key role in tumor immune evasion and is a central target in cancer immunotherapy. PD-L1 is the target of checkpoint inhibitors that block the interaction between PD-1 on T cells and PD-L1 on tumor cells, thereby preventing inhibitory signals on T cells and restoring anti-tumor T cell activity [29]. Anti-PD1 and anti-PD-L1 antibodies have shown significant therapeutic potential and efficacy in various cancers, including head and neck squamous cell carcinoma, gastric cancer, Hodgkin lymphoma, and urothelial carcinoma [30–33]. A study on PD-L1 expression in PGLs and their malignant behavior noted that PD-L1-positive PGLs are characterized by high HIF-1α expression, although this is not correlated with patient prognosis. This finding suggests that PD-L1 may participate in PGL progression through hypoxia-induced pathways, but the specific mechanisms require further investigation. CT is the preferred imaging modality for PGL, with a diagnostic sensitivity exceeding 95% for adrenal PGL, but lower sensitivity for extra-adrenal, recurrent, or metastatic PGL [34, 35]. For PGLs located at the skull base and neck, MRI has a sensitivity of 90%–95% [36]. Metaiodobenzylguanidine (MIBG), a norepinephrine analog, is absorbed and stored in chromaffin cells. 18F-FDG is a sensitive but nonspecific radiotracer taken up by cells via glucose transporters (GLUT) and is associated with increased glucose metabolism. For non-metastatic PGL, the sensitivity of 18F-FDG PET/CT (76.8%) is similar to that of 123I-MIBG SPECT/CT (75.0%). However, for metastatic PGL, 18F-FDG PET/CT shows higher sensitivity (82.5%) compared to 123I-MIBG SPECT/CT (50.0%) and CT/MRI (74.4%) [37]. Consequently, 18F-FDG PET/CT is often used for the localization and diagnosis of metastatic PGL. Surgical resection is the preferred treatment for PGL, with the primary goal being complete tumor removal to prevent rupture and local recurrence. For metastatic PGL, complete resection of the primary tumor is significantly correlated with improved patient prognosis [38]. In cases where surgery is not feasible or in the presence of distant metastases, radionuclide therapy with 131I-MIBG or 177Lu-DOTATATE is commonly used, alongside appropriate chemotherapy. The traditional first-line cytotoxic chemotherapy regimen for metastatic PGL includes cyclophosphamide, vincristine, and dacarbazine (CVD) [39]. Dacarbazine is hypothesized to be the only active agent against PGL [7], converting to the active alkylating agent MTIC (5-(3-methyl-1-triazeno)-imidazole-4-carboxamide), which is also the active metabolite of TMZ. Compared to dacarbazine, TMZ has favorable pharmacokinetics and a better toxicity profile while maintaining similar efficacy [40]. Studies have shown that TMZ is an effective chemotherapy option for many metastatic PGL patients, with greater responses reported in patients with germline SDHB mutations [6]. TMZ chemotherapy for glioblastoma (GBM) is closely associated with the methylation status of the MGMT (O6-methylguanine-DNA methyltransferase) promoter. High methylation of the MGMT promoter is correlated with a better response to TMZ, likely due to the reduced capacity of tumor cells to repair DNA damage. Methylation of the MGMT promoter silences the expression of the MGMT protein, which normally repairs DNA damage induced by alkylating agents like TMZ. Consequently, tumors with MGMT promoter methylation are more vulnerable to TMZ-induced DNA damage, leading to improved treatment outcomes. A small study on the use of TMZ in metastatic PGL also confirmed this association, with 80% of TMZ responders having a highly methylated MGMT promoter. This study also found a correlation between SDHB mutations and high MGMT promoter methylation, suggesting a potential mechanism by which SDHB mutations confer TMZ sensitivity [7–9]. After undergoing TMZ chemotherapy, the patient was regularly followed up to monitor disease progression. While no significant intracranial lesions were observed, the most recent follow-up in 2024 revealed suspected metastatic lesions in the lungs, left clavicle, abdominal lymph nodes, vertebrae, and certain ribs. The patient is currently receiving treatment with albumin-bound paclitaxel combined with anlotinib. The efficacy and prognosis of this treatment are still under observation. In conclusion, brain metastatic PGL is relatively rare and presents significant challenges in clinical practice, requiring careful consideration in diagnosis and treatment. We present a case of a primary hepatic PGL that metastasized to the brain, detailing its clinical, radiological, histopathological, and molecular characteristics, as well as the treatment process. This report aims to raise awareness of this condition, provide new insights for clinical management, and offer valuable guidance for clinicians to diagnose and treat similar cases. Supplementary Information Additional file1 (DOCX 13 KB)Additional file2 (DOCX 12 KB) Additional file1 (DOCX 13 KB) Additional file2 (DOCX 12 KB)